Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0BLFX | ISIN: SE0001137985 | Ticker-Symbol: BTPC
Frankfurt
06.06.25 | 08:04
0,017 Euro
-19,81 % -0,004
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACTIVE BIOTECH AB Chart 1 Jahr
5-Tage-Chart
ACTIVE BIOTECH AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0160,02606.06.

Aktuelle News zur ACTIVE BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.05.Active Biotech AB: Annual General Meeting of Active Biotech AB259The Annual General Meeting of Active Biotech was held on May 28, 2025. The following main resolutions were passed.In accordance with the Board of Directors' proposal, it was resolved that no dividend...
► Artikel lesen
ACTIVE BIOTECH Aktie jetzt für 0€ handeln
21.05.Active Biotech AB: Active Biotech announces patent for tasquinimod in myelofibrosis granted in Europe312Lund, May 21, 2025 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has granted the patent application 21749566.2 related to tasquinimod in myelofibrosis...
► Artikel lesen
08.05.Active Biotech AB: Active Biotech Interim Report Q1 2025404FIRST QUARTER IN BRIEFUS Patent Office granted Active Biotech's patent application for laquinimod in eye disorders (January 28)Active Biotech announced that the first patient was enrolled in the European...
► Artikel lesen
05.05.Active Biotech AB: Active Biotech reports positive top-line results from the LION study on ocular absorption and distribution of laquinimod in the eye229Daily treatment with laquinimod eye drops resulted in dose related and therapeutically relevant concentrations of laquinimod in both the anterior and posterior parts of the eye.Laquinimod eye drop treatment...
► Artikel lesen
24.02.Active Biotech AB: First patient enrolled in the HO172 clinical study of tasquinimod in myelofibrosis460Lund Sweden, February 24, 2025 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been included in the phase Ib/II clinical study of tasquinimod in patients with myelofibrosis...
► Artikel lesen
13.02.Active Biotech AB: Active Biotech Year End Report 2024335EVENTS DURING THE FOURTH QUARTEREuropean Patent Office granted Active Biotech's patent application for eye drop formulation of laquinimod (October 23)Active Biotech's clinical trial of tasquinimod in...
► Artikel lesen
28.01.Active Biotech AB: Active Biotech's patent for laquinimod in eye disorders granted in the US361Lund, January 28, 2025, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has granted Active Biotech's US patent application 17/939,109 for laquinimod in eye...
► Artikel lesen
25.11.24Nasdaq Stockholm AB: New last trading day for paid subscription shares (BTA) of Active Biotech rights issue508At the request of Active Biotech, the last trading day in Active Biotech's paid subscription shares will be changed from 2024-11-26 to 2024-12-04. Instrument: Paid subscription shares Short...
► Artikel lesen
24.10.24XFRA CAPITAL ADJUSTMENT INFORMATION - 24.10.2024735Das Instrument EGID FR0000072373 EGIDE S.A. INH. EO 2 EQUITY wird cum Kapitalmassnahme gehandelt am 24.10.2024 und ex Kapitalmassnahme am 25.10.2024 The instrument EGID FR0000072373 EGIDE S.A. INH....
► Artikel lesen
21.10.24Active Biotech AB: Active Biotech Interim Report Q3 2024868THIRD QUARTER IN BRIEFActive Biotech entered agreement with MD Anderson for a clinical study of tasquinimod in myelofibrosis (July 1)Active Biotech provided an update on the clinical phase Ib/IIa study...
► Artikel lesen
23.09.24Active Biotech AB: Active Biotech announces a rights issue of SEK 35 million421NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE...
► Artikel lesen
10.09.24Active Biotech AB: Active Biotech reports intriguing intraocular concentrations achieved in a clinical biodistribution study of laquinimod eye drops413Lund, September 10 2024 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to the ongoing clinical phase I biodistribution study of laquinimod eye drops in patients undergoing vitrectomy. A...
► Artikel lesen
22.08.24Active Biotech AB: Active Biotech Interim Report Q2 2024740SECOND QUARTER IN BRIEFStart of enrollment to the clinical phase I biodistribution study with laquinimod eye drops (April 3)Active Biotech acquired exclusive rights to patents of tasquinimod in combination...
► Artikel lesen
15.07.24Active Biotech AB: Active Biotech provides update on the clinical phase Ib/IIa study with tasquinimod in relapsed refractory multiple myeloma461Lund, July 15 2024 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to a clinical study of tasquinimod in patients with relapsed refractory multiple myeloma (RRMM) being conducted...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1